Skip to content

Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis

Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05090982
Acronym
SHADOW
Enrollment
150
Registered
2021-10-25
Start date
2021-12-31
Completion date
2022-11-30
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

Atopic Dermatitis, shared medical decision-making tool, e-Delphi

Brief summary

Hypothesis/Objective : Patient-centered health care and shared decision making are key components of increasing importance which are recommended by the French Haute Autorite de Sante (HAS) and World Health Organization (WHO). In the context of dermatology and atopic dermatitis, European guidelines has promoted an active involvement from both patients and caregivers in therapeutic decisions at all stages to achieve therapeutic success and the Task Force on Atopic Dermatitis (ETFAD) has promoted the setting of treatment goals in a shared decision with the patient. The main objective of this study is to develop and cross culturally validate a tool dedicated to shared-decision in atopic dermatitis that can be used during routine dermatological consultations. The second objective is to better characterize patients seen in this context and to evaluate patients' satisfaction when empowered by shared decision. Method : We aim to develop a SDMt in AD following the recommendations of the International Patient Decision Aid Standards (IPDAS) collaboration. Development will use a multistep approach: 1) identification of priority domains for patients; 2) Selection of domains to be included in the SDMt for AD; and 3) Creation and testing of the SDMt. Participants will be consecutive adult (\>18 years old) patients attending consultation for a AD in medical centres in France (Toulouse, Nantes and Créteil). All participants will provide written consent to participate. The study will be submitted for approbation to the local ethics committees of the University Hospital Centres of Paris and will be conducted according to the Declaration of Helsinki. Step 1: Identification of priority domains for patients Step 2: Selection of domains to be included in the SDMt for AD Step 3: Creation and testing of the SDMt

Interventions

OTHERAudio recordings during the consultations

50 patients with audio recordings of the consultation

OTHERAudio recordings during the consultations and test of the shared medical decision-making tool for modification

50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification

OTHERAudio recordings during the consultations and test of the shared medical decision-making tool for validation

50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years, male or female. * Patient with atopic dermatitis * Written information given to the patient and no objection from the patient to participate to the study

Exclusion criteria

* Patient under guardianship or curatorship * Patient with cognitive dysfunction that makes it impossible to communicate effectively or to complete the questionnaire * Patient under AME

Design outcomes

Primary

MeasureTime frameDescription
Creation of a shared medical decision-making tool in the context of a consultation for atopic dermatitis in a specialized dermatology consultation.through study completion, an average of 1 yearQualitative descriptions of the topics discussed by the patient during the therapeutic decision in a specialized dermatology consultation for atopic dermatitis; in other words, to characterize the topics discussed by the patient during the consultation

Secondary

MeasureTime frameDescription
Assessment of the perceived state of the patient about the interventionduring the interventionValidation tool score CollaboRATE
Assessment of the psychological state of the patientduring the interventionValidation tool score GAD-7
Assessment of the perceived health state of the patientduring the interventionScore of PHQ-9 questionnaire
Patient satisfaction with the therapeutic decision-making processduring the interventionSURE satisfaction score
Assessment of the stigmatization perceived by the patientduring the intervention6-items Stigmatization scale
Assessment of the severity perceived by the patientduring the interventionAtopic Dermatitis Perceived Severity Scale
Description of treatment compliance in patients who received the validated toolduring the interventionCompliance with treatment received
Assessment of the quality of life of the patientduring the interventionScore of DLQI questionnaire

Countries

France

Contacts

Primary ContactKhaled Ezzedine, MD
khaled.ezzedine@aphp.fr(0)149812504

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026